tbuckley/cabot-search huggingface dataset:
SAT0021 Prognostic Value of Salivary Gland Ultrasonography (SGUS) in Primary SjÖGren's Syndrome
Authors: C. Baldini, N. Luciano, F. Sernissi, D. Martini, F. Francesco, T. Gaia, M. Mosca, S. Bombardieri
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> Recently, salivary gland ultrasonography (SGUS) has been presented as a promising diagnostic tool for primary Sjögren9s syndrome (pSS). The aim of the current study was to assess the prognostic value of SGUS in the assessment and risk stratification of pSS patients into high or low risk subgroups with regard to lymphoma development and systemic complications. <h3>Methods</h3> Unselected patients with a diagnosis of pSS made according to the AECG 2002 criteria were consecutively enrolled in this study. Patients9 clinical and serological features were prospectively collected particularly focusing on variables generally associated to pSS severity. The ESSDAI score was calculated to quantify pSS disease activity. SGUS was carried out by the same radiologist and the following US parameters were recorded: size, parenchymal echogenicity and inhomogeneity in the parotid and submandibular glands on both sides. A modified version of a previously reported ultrasound scoring system (De Vita et al 1992, cut-off&gt;2) was used to grade the echostructure alterations of the salivary glands. Comparison in terms of continuous data were determined using independent sample t tests or Mann–Whitney tests, and in terms of proportions using contingency table analysis and chi square test. Spearman9s rank correlation coefficients were calculated between SGUS scores and disease duration, age at the diagnosis, ESSDAI score, IgG levels, C3 and C4 levels, white blood cells, minor salivary gland focus score (MSG FS) and salivary flow rate. <h3>Results</h3> One hundred and sixty female patients with pSS were enrolled in this study (median age=57.5 years (IQR 46.25-68); median follow-up=3 years (IQR 1-8). A pathological SGUS score ≥2 was found in 66/160 (41%) patients. Abnormal SGUS scores were significantly more frequent in patients with a systemic disease with respect to those with a pure "exocrinopathy", and in those with a positivity for anti-Ro/SSA antibodies. A positive correlation was observed between the SGUS score and ESSDAI (r=0.525; p&lt;0.0001), ESR (r=0.223; p=0.02) and higher levels of IgG (r=0.249; p=0.02). A negative correlation was found between the SGUS score and the age of the patients (r=-0.205; p=0.003), C4 levels (r=-0.221; p=0.02), white blood cells count (r=-0.207; p=0.02) and salivary flow rate (r=-0.295; p&lt;0.0001). <h3>Conclusions</h3> Our findings outline the usefulness of SGUS for the identification of patients with high disease activity and support its routinary use in pSS assessment. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4468
Abstract 1349: Xenograft models of human acute myeloid leukemia (AML) with biomarker strategies are valuable in development of new drugs targeting AML
Authors: Lan Zhang, Taiping Chen, Qian Shi, Juan Zhang
Journal: Cancer Research (2012)

Abstract Acute myeloid leukemia (AML) is a malignant disease caused by disorder of progenitor cells in myeloid hematopoiesis. The rapid progress and high fatality make it difficult to cure the patients suffering from AML. Choice of treatment is limited, consisting primarily of chemotherapy and hematopoietic stem cell transplantation. Pharmaceutical companies are focused on designing new drugs that may be efficacious in treating the disease and prolong the survival of the patients. However, the lack of AML model and specific biomarkers hinder the progress of research on this cancer type. Here we successfully validated subcutaneous and systemic models derived from a number of AML cell lines, such as MV4-11, HL-60, Molm-16, and ML-2, in NOD/SCID mice to evaluate the antitumor activities of new compounds. Biomarkers, such as CD45, CD38 and CD15 in PBMC, spleen and bone marrow from the systemic models, are used in detecting and monitoring the disease progress. These biomarkers correlated with tumor take rate, disease progression and response to standard of care treatments. In conclusion, AML xenograft models with biomarker strategies provide valuable platforms for the development of new compounds targeting this deadly disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1349. doi:1538-7445.AM2012-1349
FRI0023 Toll-like receptors 1,2,4,6, MYD88, NALP3 and IL1A have no effect in a murine model of osteoarthritis
Authors: S. Nasi, H.-K. Ea, F. Lioté, A. So, N. Busso
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Innate immune response components such as Toll-like receptors (TLRs), NLRP3 inflammasome and the intracellular signaling molecule MyD88 are all expressed by synovial membrane and chondrocytes. Previous studies have shown that TLRs and NLRP3 inflammasome act in concert to increase IL-1β secretion by activated synovial macrophages and that IL-1β could be an important mediator involved in the pathogenesis of osteoarthritis (OA). <h3>Objectives</h3> The aim of our study was to evaluate the role of various TLRs, NLRP3, IL1α and the signaling molecule MyD88 in a murine model of OA induced by knee menisectomy (MNX, surgical removal of the medial meniscus). <h3>Methods</h3> Knees from 8-10 weeks old C57Bl6 wild type female (n=7), knock-out TLR-1 (n=5), -2 (n=7), -4 (n=8) -6 (n=5), NLRP3 (n=9), IL1α (n=5) or MyD88 (n=7) were menisectomized, using the sham-operated contralateral knee as a control. 8 weeks later mice were sacrificed and knee cartilage destruction evaluated by histology using the OARSI scoring method. In addition, apoptotic chondrocytes were quantified in MyD88- and NLRP3-deficient knees. Finally, synovial inflammation was also scored. <h3>Results</h3> Operated knees exhibit OA symptoms at 8 weeks post-surgery compared to sham-operated knees as evidenced by both femoral and tibial cartilage degradation (increased OARSI score parameters, increased chondrocyte apoptosis) and by synovial inflammation. In menisectomized TLR-1, -2, -4, and -6 deficient mice, severity and extent of cartilage lesions and synovial inflammation were similar to that in MNX wild-type mice. Using the same approach, we determined that there was no significant difference in phenotype betweeen the NLRP3- or IL1α- deficient mice and wild-type control mice. Accordingly, we did not observed a significant effect of MyD88 deletion, as cartilage erosion and synovial inflammation were similar in MNX knock-out and wild-type mice. <h3>Conclusions</h3> Knee MNX recapitulates features of OA, i.e, cartilage destruction and synovial inflammation. Deficiency of TLRs, NLRP3 inflammasome and their signalling molecule MyD88 did not impact on the severity of experimental OA. Our results suggest that NLRP3 inflammasome is either not involved in IL-1β activation or that IL-1β is not a key mediator in this murine OA model. This latter hypothesis is strengthened by the lack of efficiency of IL-1β antagonists in the treatment of OA. <h3>Disclosure of Interest</h3> None Declared
Safe Conduct of the Patient through Cardiac Surgery
Authors: Harrison Black, Dwight E. Harken
Journal: New England Journal of Medicine (1954)

AFTER decades of sporadic though brilliant attempts at cardiac surgery intense activity in this field in the past eight years has resulted in a vast new area of surgical accomplishment. These advances could only have been made against the background of knowledge of anesthesia and respiratory physiology gained during the development of thoracic surgery since the early 1930's. In similar fashion the early efforts in the cardiac field were directed toward devising technics for safe operation within the cardiac chambers and the elucidation of the physiologic principles necessary for survival during the immediate operative period. It is not presumed that . . .
S100 Natural History of Renal Angiomyolipoma in Sporadic and Tuberous Sclerosis Complex Associated Lymphangioleiomyomatosis: Implications For Clinical Care
Authors: ZW Yeoh, V Navaratnam, RB Hubbard, SR Johnson
Journal: Thorax (2012)

<h3>Background</h3> Lymphangioleiomyomatosis (LAM) is a rare disease of women categorised by lung cysts, lymphatic abnormalities and angiomyolipomas; a benign tumour occurring chiefly in the kidneys. Although benign, the tumours can enlarge causing symptoms and those over 4cm are prone to haemorrhage which can result in nephrectomy. LAM can occur in isolation (sporadic LAM) or associated with tuberous sclerosis complex (TSC-LAM). Treatment guidelines for angiomyolipoma tend to be based on retrospective series often from patients with TSC. The natural history of angiomyolipoma in sporadic LAM is not well understood. <h3>Aims</h3> To document the natural history, risk factors for, and clinical features associated with, angiomyolipoma in a national cohort of patients with sporadic and TSC-LAM to plan clinical screening programs. <h3>Methods</h3> Demographic data, clinical features, lung function and tumour size were obtained from clinical records of patients attending the National Centre for LAM in Nottingham. Tumour size was recorded as the longest tumour diameter on any imaging modality. Tumours smaller than 10mm were assigned a value of 10mm. Ethical approval for use of patient data was obtained and patients gave informed consent. <h3>Results</h3> 122 patients with definite or probable LAM by European Respiratory Society criteria were identified. Of these, 68 (56%) had at least one angiomyolipoma. Angiomyolipoma were present in 50% of patients with sporadic LAM and all patients with TSC-LAM. Those with sporadic LAM tended to have smaller tumours than those with TSC-LAM (31mm (SD 27) vs. 49mm (SD 27) respectively), were less often bilateral (40 vs. 79%), were less likely to bleed (17 vs. 31%) and less likely to require surgery or embolisation (49 vs. 66%). Serial tumour measurements were available from some patients, tumours from those with TSC-LAM grew at 3.8 mm/year (n=6, SD 14.2) tumour growth in sporadic LAM growth was 4.3 mm/year (n=16, SD 8.2. p=0.46). <h3>Conclusions</h3> Angiomyolipomas are common in patients with sporadic and TSC-LAM. The tumours require intervention more frequently in TSC than sporadic LAM. The two patient groups may require different angiomyolipoma management.
MRI and FDG PET/CT Findings of Malignant Fibrous Histiocytoma of the Prostate
Authors: Aisheng Dong, Jing Gong, Yang Wang, Changjing Zuo
Journal: Clinical Nuclear Medicine (2013)

Malignant fibrous histiocytoma primarily arising from the prostate is extremely rare. A 43-year-old man presented with dysuria for 12 months. Serum prostate-specific antigen level was normal. T2-weighted MR images showed a well-circumscribed tumor with inhomogeneous intensity in the prostate. The patient underwent transurethral resection of the prostate. Prostate malignant fibrous histiocytoma was histopathologically confirmed. FDG PET/CT was performed showing extremely high FDG uptake of the tumor with SUVmax of 46.8.
THE KINETICS OF INDIUM-111-NEUTROPHIL UPTAKE AND SURVIVAL IN INFECTED WOUND CYLINDERS IN THE DOG.
Authors: David C. Price, Philip B. Paty, Ronald W. Graeff, Stephen J. Mathes
Journal: Clinical Nuclear Medicine (1987)

Price, David C.; Paty, Philip B.; Graeff, Ronald W.; Mathes, Stephen J. Author Information
Diagnostic yield of EUS-FNA for gastroduodenal submucosal tumors (SMTs)
Authors: Tomono Teruko
Journal: Endoscopy (2011)

It's difficult to diagnose the etiology of submucosal tumors (SMTs) by radiological or endoscopic images alone, and therefore we used EUS-FNA to obtain a pathological diagnosis. The aim of this retrospective study was to evaluate the diagnostic yield of EUS-FNA for gastroduodenal SMTs, the frequency of adequate specimens for pathological evaluation, and to compare the results with post-surgical specimens.
Do children with optic pathway tumors have an increased frequency of other central nervous system tumors?
Authors: David N. Korones, Jeannie Padowski, Brad A. Factor, Louis S. Constine
Journal: Neuro-Oncology (2003)

We questioned whether children with optic pathway tumors (OPTs) have an increased frequency of other CNS tumors on the basis of experience with a number of such children treated at our institution. The medical records of all patients with OPTs treated at Golisano Children's Hospital at Strong at the University of Rochester from 1957 to 2000 were reviewed to determine the incidence of additional CNS tumors in these children and whether the occurrence of these other CNS tumors is associated with any risk factors. Twenty-six children had OPTs. Twelve of the 26 children had biopsy-proved tumors; the remaining 14 were diagnosed on the basis of CT or MRI scans. Eight of the 26 patients (31%) had a total of 11 additional CNS tumors. (One child had 2 additional CNS neoplasms, and a second child had 3.) Nine were biopsy proved (3 glioblastoma, 3 anaplastic astrocytoma, 3 low-grade astrocytoma), and 2 were diagnosed by imaging studies alone (acoustic neuromas). Eight of the 11 tumors occurred at a median of 5 years (0.8-25 years) subsequent to the diagnosis of the OPTs; 3 were diagnosed simultaneously with the OPT. Of the 17 children with neurofibromatosis (NF) and OPTs, 8 (47%) had additional CNS tumors, while none of the 9 children (0%) without NF had other CNS tumors (P = 0.023). There was no association between radiation treatment of the primary OPT and subsequent development of other CNS tumors in the group as a whole, or when the analysis was confined to children with NF. Despite this lack of statistical association, all 7 CNS tumors that occurred following radiation arose in irradiated areas. The risk of simultaneous or subsequent CNS tumors in children with NF and OPTs is high. These children should be closely monitored for the simultaneous or subsequent occurrence of other CNS tumors.
Abnormalities of Immunoregulatory T Cells in Disorders of Immune Function
Authors: Ellis L. Reinherz, Arye Rubinstein, Raif S. Geha, Anthony J. Strelkauskas, Fred S. Rosen, Stuart F. Schlossman
Journal: New England Journal of Medicine (1979)

We studied a five-year-old girl with several autoimmune disorders and a 16-year-old boy with acquired agammaglobulinemia to determine whether aberrations of immunoregulatory T cells could explain some instances of immunodeficiency or autoimmunity. The normal peripheral blood T-cell population, as defined by specific heteroantiserums, is 20 per cent TH2+ and 80 per cent TH2-. Human suppressor cells are TH2+, whereas helper cells are TH2-. In addition, each subset expresses Ia antigens upon activation. Our patient with autoimmune disease had no demonstrable TH2+ cells, and her lymphocytes could not be induced to suppress. Her circulating T cells were of an activated-helper phenotype, i.e., TH2-,Ia+. In contrast, in the boy with agammaglobulinemia, the T-cell population was predominantly of an activated-suppressor phenotype, i.e., TH2+,Ia+. This patient's T cells abrogated both his own and his histoidentical brother's B-cell secretion of immunoglobulins. We conclude that the characterization of T cells may provide insight into the causes of a number of abnormal immune states in man.
EFICACIA Y SEGURIDAD DEL TRATAMIENTO ENDOSCOPICO DE LOS TUMORES DE PAPILA: NUESTRA EXPERIENCIA
Authors: T Revuelto Artigas, Y Arguedas Lázaro, A Lué, P Lacarta García, Y Ber Nieto, C Aznar, MA Simón Marco, J Ducons García
Journal: Endoscopy (2012)

Introducción: Los tumores de papila representan un 5% de las neoplasias gastrointestinales. Presentan un conocido potencial maligno por lo que la resección es la norma. La ampulectomía endoscópica puede ser usada como terapéutica alternativa a la cirugía, aunque el método de resección y el período de vigilancia no están bien establecidos. Objetivos: Evaluar la eficacia y seguridad de la ampulectomía endoscópica realizada en nuestro centro. Método: Estudio retrospectivo de serie de casos en los que se ha realizado ampulectomía desde noviembre de 2009 a junio de 2012. Se realizó abordaje con duodenoscopio, infiltración de la base con adrenalina y resección con asa de polipectomía, la mayoría fragmentada, esfinterotomía y colocación de prótesis biliopancreáticas de seguridad. Se valoran las siguientes variables: la eficacia (ausencia de tumor macroscópico) y seguridad (las complicaciones tras la técnica) Resultados: Se trataron 11 pacientes (9H y 2M) con una edad media de 67 años. La estadificación por ecoendoscopia fue 27% de los casos T1 mientras los restantes eran T2, con un tamaño medio de 2cm. Un 27% de los casos con displasia de bajo grado, 45% displasia moderada, 9% displasia grave y 18% carcinoma in situ. Se realizó seguimiento de los pacientes a los 3, 6 y 12 meses. 5 de los pacientes cumplieron el año de seguimiento y los restantes 6meses. En 8 pacientes se consiguió resecar completamente aunque precisaron realizar más de una sesión de tratamiento (2sesiones de media). El 27% de los casos presentaron recidiva tras la primera resección, realizándose otra nuevamente. 72% presentaron irregularidad (con biopsias que confirmaban recidiva microscópica) tratándose los bordes con coagulación con Argón, siendo normal la cicatriz en el seguimiento posterior.Al año de seguimiento el 100% de los pacientes presentó ausencia de recidiva.2 pacientes precisaron cirugía para el tratamiento, en menos de 6 meses (falleciendo uno de ellos por complicaciones tras la intervención).Tras la ampulectomía endoscópica se presentaron un 54% de complicaciones precoces leves: dolor abdominal que cedió con analgesia (4/11) pancreatitis aguda (1/11) y sangrado leve que no precisó transfusión (1/11). Hubo un 63,3% de complicaciones tardías (primeros 6 meses): estenosis papilar (3/11) y colangitis (4/11) que precisaron nueva CPRE. No se presentó mortalidad asociada a la técnica. Conclusiones: La ampulectomía endoscópica es una técnica eficaz aunque precisa de más de un tratamiento endoscópico para su solución. Las complicaciones que se presentaron de forma aguda fueron leves y las crónicas se pudieron resolver tras la realización de una nueva técnica endoscópica.
Increased Hyperthermic Response With Prostaglandin E1 in VX2 Liver Carcinoma in Rabbits
Authors: M. Morita, H. Kuwano, H. Matsuda, M. Mori, K. Sugimachi
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Increased Hyperthermic Response With Prostaglandin E 1 in VX2 Liver Carcinoma in Rabbits Get access Masaru Morita, Masaru Morita * Department of Surgery II, Faculty of Medicine, Kyushu UniversityFukuoka, Japan * Correspondence to: Masaru Morita, M.D., Department of Surgery II, Faculty of Medicine, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hiroyuki Kuwano, Hiroyuki Kuwano Department of Surgery II, Faculty of Medicine, Kyushu UniversityFukuoka, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hiroyuki Matsuda, Hiroyuki Matsuda Department of Surgery II, Faculty of Medicine, Kyushu UniversityFukuoka, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Masaki Mori, Masaki Mori Department of Surgery II, Faculty of Medicine, Kyushu UniversityFukuoka, Japan Present address: M.Mori,New England Deaconess Hospital, Harvard Medical School,Boston Mass Search for other works by this author on: Oxford Academic PubMed Google Scholar Keizo Sugimachi Keizo Sugimachi Department of Surgery II, Faculty of Medicine, Kyushu UniversityFukuoka, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 19, 2 October 1991, Pages 1395–1400, https://doi.org/10.1093/jnci/83.19.1395 Published: 02 October 1991 Article history Received: 01 April 1991 Revision received: 12 June 1991 Accepted: 10 July 1991 Published: 02 October 1991
A1.7 The regulation of human in vitro TH17 cell differentiation
Authors: E Baricza, E Lajkó, L Kőhidai, B Molnár-Érsek, N Marton, E Buzás, Gy Nagy
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background and objectives</h3> Th17 cells produce several inflammatory cytokines, such as interleukin (IL)-17A, -17F, -21, -22, and tumour necrosis factor-α and play an important role in the regulation of inflammation. We studied <i>in vitro</i> Th17 cell differentiation of healthy donors and patients with rheumatoid arthritis (RA). <h3>Materials and methods</h3> CD4<sup>+</sup> T cells were negatively separated by magnetic method from peripheral blood mononuclear cells (PBMC) then CD45RO+ and CD45RO- cells were separated. The cells were treated for 5–10 days with anti-CD3 and anti-CD28 antibodies and with TGFβ (2.5 ng/ml) and IL-6 (25 ng/ml) or with IL-6 (25 ng/ml), IL-1 (10 ng/ml) and IL-23 (10 ng/ml) cytokines and with anti-IL-4 (10 μg/ml) and anti-IFNγ (10 μg/ml) blocking antibodies. The IL-17 and IL-22 production were measured by ELISPOT and ELISA, the RORγt expression was measured by real-time PCR and by Western blot methods. Cell viability was monitored by Trypan blue staining, by Annexin V binding and by an impendance-based cell analyser. <h3>Results</h3> Anti-CD3/CD28 activation increased the IL-17 production, but did not alter the RORγt expression. The anti-CD3/CD28 activation and TGFβ, IL-6, and IL-1 cytokine induced RORγt expression of the CD4<sup>+</sup> T cells was further increased by the anti-IL-4 and anti-IFNγ antibody treatment. The IL-22 production of CD4<sup>+</sup> T cells was significantly reduced in the RORγt producing CD4<sup>+</sup> cells. The CD45RO+ cells expressed high level of RORγt and produced high amount of IL-17 without stimulation or cytokine treatment. The RORγt expression of the CD4<sup>+</sup>RO- T cells increased severalfold upon stimulation and cytokine treatment. The differentiated Th17 cells of patients with RA produced more IL-17 than those of the healthy donors'. The applied treatments did not change the viability of the cells. <h3>Conclusions</h3> Our results suggest that the IL-17 and IL-22 production are differently regulated during Th17 differentiation. The Th17 cell differentiation is most effective from CD45RO- naive T cells.